HIPEC Surgery and Hemodynamics

Perioperative Hemodynamic and Respiratory Changes During Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Cytoreductive Surgery

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06922227

Enrollment

Registered

2025-04-10

Start date

2025-04-01

Completion date

2025-07-15

Last updated

2025-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytoreductive Surgery, Hemodynamics, Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Keywords

HİPEC, cytoreductive surgery, Hemodynamics

Brief summary

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) involves the intraoperative administration of heated chemotherapeutic agents into the abdominal cavity following cytoreductive surgery (CRS). The increasing use of CRS combined with HIPEC has introduced certain procedural and physiological considerations that distinguish it from other surgical interventions, posing unique challenges for researchers and clinicians alike. Despite advancements in surgical and anesthetic techniques, this combined approach is frequently associated with significant hemodynamic instability, coagulation abnormalities, respiratory complications, and nutritional imbalances. The study aims to contribute to the existing body of knowledge by examining the physiological alterations induced by HIPEC, thereby offering practical insights and guidance for investigators involved in the management and study of this complex therapeutic modality.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ≥18 years old Patients planned to undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy * ASA II-III-IV physical class

Exclusion criteria

* \<18 years * Emergency cases

Design outcomes

Primary

Measure	Time frame	Description
physiological parameter; systolic/diastolic blood pressure	Intraoperatively	Systolic/diastolic blood pressure will be recorded in mmHg every 10 minutes.
anesthesia device measurement parameter; EtCo2	Intraoperatively	EtCo2 will be recorded every 10 minutes as mmHg.
anesthesia device measurement parameter; Pmax	Intraoperatively	Pmax will be recorded as cmH2O every 10 minutes.
physiological parameter ; heart rate	Intraoperatively	HIPEC is usually the application of chemotherapy that lasts between 45 and 90 minutes after the end of cytoreductive surgery. During HIPEC application (45-90 minutes), Heart rate: will be recorded every 10 minutes as beats / minute.
physiological parameter; SpO2	Intraoperatively	SpO2 will be recorded as percent every 10 minutes.

Secondary

Measure	Time frame	Description
Postoperative data	24 hours after surgery	The patient's general condition before discharge, and any complications related to surgery will be recorded.
Preoperative data	24 hours before surgery	In the preoperative period, the patient's additional diseases, medications used, surgical history, and ASA score will be recorded.

Countries

Turkey (Türkiye)

Contacts

Primary ContactMiray G Özdemir

miraygozdebinzet@gmail.com+905347816151

Outcome results